Category: biotech

.In the middle of a yearslong medical trial downtrend in the U.K., a brand-new public-private alliance has surfaced in efforts to reinvigorate the nation’s pharmaceutical

.Turnstone Biologics is lowering its head count by 60% and shocking its C-suite in order to always keep the capital to its own only clinical-stage

.Transgene’s therapeutic injection prospect TG4001 has flunked a period 2 strong lump test. But, while the prospect failed to boost progression-free survival (PFS), the French

.Tracon Pharmaceuticals has made a decision to unwind procedures weeks after an injectable immune gate inhibitor that was accredited from China flunked a pivotal test

.After escaping a medical hold many years back, Dyne Rehab has disclosed brand new period 1/2 data for its Duchenne muscular dystrophy (DMD) therapy DYNE-251.

.Alaunos Rehabs is actually axing a deal with Precigen, losing hope licensing legal rights to an individualized T-cell platform.The licensing arrangement go back to 2018

.Amidst a reconstruction initiative that is actually renewed combination common as well as cutting-edge medicines player Teva, the provider is leaning into unfamiliar medicines and

.Terray Therapeutics has generated $120 thousand for a collection B fundraise as the AI-focused biotech goals to change little molecule medicine growth.Brand new capitalist Bedford

.Terns Pharmaceuticals’ choice to lose its liver condition ambitions may however repay, after the biotech posted phase 1 records revealing some of its various other

.Invite to this week’s Chutes &amp Ladders, our roundup of notable leadership hirings, firings and retirings throughout the sector. Feel free to send the compliment–